SCHEDULE 13G/A: RTW Investments and Dr. Roderick Wong Disclose 1.5% Stake in Dyne Therapeutics

RTW Investments, LP and its Managing Partner, Dr. Roderick Wong, have filed an amended Schedule 13G, reporting a beneficial ownership of 1.5% in Dyne Therapeutics, Inc.'s common stock as of March 31, 2025.

Summary

• RTW Investments, LP, a Delaware limited partnership and investment adviser, along with its Managing Partner and Chief Investment Officer, Roderick Wong, M.D., have filed an Amendment No. 2 to Schedule 13G.
• The filing reports their beneficial ownership in Dyne Therapeutics, Inc. (NASDAQ: DYN) common stock.
• As of March 31, 2025, the Reporting Persons collectively beneficially own 1,690,567 shares of Dyne Therapeutics common stock.
• This ownership represents 1.5% of the company's outstanding common stock.
• The percentage is calculated based on 113,633,782 shares outstanding as of April 4, 2025, as reported in Dyne Therapeutics' Definitive Proxy Statement on Schedule 14A filed on April 15, 2025.
• RTW Investments and Dr. Wong share both voting and dispositive power over all 1,690,567 shares.
• The shares are held directly by the RTW Funds, for which RTW Investments acts as investment adviser.

Sentiment

Score: 5

Explanation: The document is a factual, regulatory filing disclosing beneficial ownership. It provides no operational or financial performance data for Dyne Therapeutics, Inc., and thus has a neutral sentiment score. The disclosure of an investment by RTW Investments could be seen as mildly positive by some, but the filing itself is purely informational.

Positives

• The filing indicates continued investment by RTW Investments, a specialized healthcare investment firm, which may be viewed as a vote of confidence in Dyne Therapeutics' long-term prospects.

Negatives

• This filing is a routine disclosure of ownership and does not contain information that would typically be categorized as negative regarding the company's operations or financial performance.

Risks

• This Schedule 13G filing is a disclosure of beneficial ownership and does not detail specific risks related to Dyne Therapeutics, Inc.'s business operations or financial health. The risks associated with the investment are inherent to the company's business and market conditions, not the ownership disclosure itself.

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance regarding Dyne Therapeutics, Inc.'s future performance, strategic plans, or financial outlook.

Management Comments

• The document does not contain direct quotes or paraphrased statements from Dyne Therapeutics' management. It contains certifications from Roderick Wong, M.D. as Managing Partner of RTW Investments, LP, and in his individual capacity, stating that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Industry Context

This filing is a routine disclosure required by the SEC when an investor's beneficial ownership of a company's stock reaches or exceeds 5% (initial filing) or when there are material changes to previously reported ownership (amendments). For a specialized healthcare investment firm like RTW Investments, holding a stake in a biotechnology company like Dyne Therapeutics is consistent with their investment strategy. Such filings provide transparency into significant institutional holdings, which can be of interest to other investors tracking smart money movements in the biotech sector.

Comparison to Industry Standards

• This document is a standard Schedule 13G filing, which is a regulatory requirement for disclosing beneficial ownership. It does not provide operational or financial results that can be directly compared to industry standards or specific comparable companies/projects. The 1.5% stake held by RTW Investments is a relatively small passive investment, typical for an institutional investor that is not seeking to control or significantly influence the company.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake in the company, which can inform investment decisions.
• Investment Community: Offers insight into the holdings of RTW Investments, a notable player in healthcare investments.

Next Steps

• The document itself does not outline any specific future actions, events, or milestones for Dyne Therapeutics, Inc. or the Reporting Persons beyond the regulatory filing requirements.

Key Dates

Keywords

Dyne Therapeutics, RTW Investments, Roderick Wong, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, Biotechnology, Healthcare Investment, SEC Filing